FI109207B - Tumör/kolhydratantigenspecifik monoklonal antikropp samt cellinje - Google Patents

Tumör/kolhydratantigenspecifik monoklonal antikropp samt cellinje Download PDF

Info

Publication number
FI109207B
FI109207B FI935970A FI935970A FI109207B FI 109207 B FI109207 B FI 109207B FI 935970 A FI935970 A FI 935970A FI 935970 A FI935970 A FI 935970A FI 109207 B FI109207 B FI 109207B
Authority
FI
Finland
Prior art keywords
antibody
tyr
cell line
leu
antigen
Prior art date
Application number
FI935970A
Other languages
English (en)
Finnish (fi)
Other versions
FI935970A (fi
FI935970A0 (fi
Inventor
Jan Holmgren
Peter Lind
Leif Lindholm
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of FI935970A publication Critical patent/FI935970A/fi
Publication of FI935970A0 publication Critical patent/FI935970A0/fi
Application granted granted Critical
Publication of FI109207B publication Critical patent/FI109207B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (6)

18 109207
1. Antikropp för CA-242-antigen för annan än terapeutisk användning, känne-tecknad av att den produceras av hybridomcellinje C242:II, som har ECACC-identifikationsnummer 90012601, eller av en antikropp som har väsentligen samma 5 antikroppsbindningsegenskaper (epitopspecificitet).
2. Monoklonal antikropp i enlighet med patentkrav 1, kännetecknad av att den används diagnostisia in vivo.
3. Antikropp i enlighet med patentkrav 1 eller 2, kännetecknad av att den är i fragmenterad form.
4. Antikropp i enlighet med vilket som heist av patentkraven 1-3, kännetecknad av att den binder sig specifikt vid samma epitop som antikroppen, som har i sinä CDR-omräden: κ-kedja: CDR1: Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr 15 CDR2: Arg Met Ser Asn Leu Vai Ser CDR3: Leu Gin His Leu Glu Tyr Pro Phe Thr :' Tung kedja: [·' ' CDR1: Tyr Tyr Gly Met Asn • ‘ ; CDR2: Trp Ile Asp Thr Thr Thr Gly Glu Pro Thr Tyr Ala Glu Asp Phe Lys Gly • ‘ 20 CDR3: Arg Gly Pro Tyr Asn Trp Tyr Phe Asp Vai. •;" | 5. Förfarande för in vitro diagnosticering, kännetecknat av att i det bringas ett • ·. prov i kontakt med en monoklonal antikropp i enlighet med vilket som heist av pa- , tentkraven 1-4 i förhällanden, i vilka det bildas ett komplex innehällande den mo- : noklonala antikroppen bunden vid sin antigen, och därefter bestäms komplexet som 25 formats, vars mängd korrelerar med mängden antigen som firms i provet.
6. Cellinje, kännetecknad av att det är en hybridomcellinje C242:II, som har • ECACC-identifikationsnummer 90012601. 109207 I S ro ro I s Fig. 1
FI935970A 1991-07-03 1993-12-31 Tumör/kolhydratantigenspecifik monoklonal antikropp samt cellinje FI109207B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9102074 1991-07-03
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody
PCT/SE1992/000502 WO1993001303A1 (en) 1991-07-03 1992-07-03 Tumor, carbohydrate antigen specific monoclonal antibody and cell line
SE9200502 1992-07-03

Publications (3)

Publication Number Publication Date
FI935970A FI935970A (fi) 1993-12-31
FI935970A0 FI935970A0 (fi) 1993-12-31
FI109207B true FI109207B (sv) 2002-06-14

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935970A FI109207B (sv) 1991-07-03 1993-12-31 Tumör/kolhydratantigenspecifik monoklonal antikropp samt cellinje

Country Status (19)

Country Link
US (1) US5552293A (sv)
EP (1) EP0521842B1 (sv)
JP (1) JP3194020B2 (sv)
KR (1) KR100246681B1 (sv)
AT (1) ATE171193T1 (sv)
AU (2) AU2292092A (sv)
CA (1) CA2073124C (sv)
DE (1) DE69226990T2 (sv)
DK (1) DK0521842T3 (sv)
EE (1) EE03031B1 (sv)
ES (1) ES2124250T3 (sv)
FI (1) FI109207B (sv)
HU (2) HU218084B (sv)
IE (1) IE80841B1 (sv)
IL (1) IL102390A (sv)
NO (1) NO315472B1 (sv)
NZ (1) NZ243435A (sv)
SE (1) SE9102074D0 (sv)
WO (2) WO1993001302A1 (sv)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1411962B1 (en) * 2001-03-15 2011-01-19 Neogenix Oncology, Inc. Monoclonal antibody therapy for pancreas cancer
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
US20060246060A1 (en) * 2002-07-02 2006-11-02 Nesta Douglas P Novel stable formulation
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
DK1651162T3 (en) 2003-05-20 2016-02-01 Immunogen Inc IMPROVED CYTOTOXIC AGENTS WITH NEW MAYTANSINOIDS
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US20060182750A1 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing stable drug conjugates
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
NZ595386A (en) * 2005-08-11 2013-08-30 Arpi Matossian Rogers Peptides for treatment and diagnosis of autoimmune disease
EP1928503B1 (en) 2005-08-24 2012-10-03 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
KR20160039295A (ko) 2008-08-05 2016-04-08 도레이 카부시키가이샤 암의 검출 방법
PL2437790T3 (pl) 2009-06-03 2019-09-30 Immunogen, Inc. Sposoby sprzęgania
KR20220123130A (ko) 2011-03-29 2022-09-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
EP3220959A1 (en) 2014-11-19 2017-09-27 ImmunoGen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
KR20180100412A (ko) 2016-01-10 2018-09-10 네오티엑스 테라퓨틱스 엘티디. 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
RU2018130108A (ru) 2016-02-05 2020-03-06 Иммуноджен, Инк. Эффективный способ получения конъюгатов связывающийся с клеткой агент цитотоксический агент
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
AU2020275142A1 (en) 2019-05-15 2021-12-16 Neotx Therapeutics Ltd. Cancer treatment
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
JPH06500077A (ja) * 1990-07-20 1994-01-06 カビ・フアーマシア・アクチエボラーグ 接合体物質、試薬および新規なポリエーテル
ES2094231T3 (es) * 1990-07-20 1997-01-16 Pharmacia & Upjohn Ab Conjugados de anticuerpos superantigenos especificos de una diana y su preparacion.

Also Published As

Publication number Publication date
ES2124250T3 (es) 1999-02-01
WO1993001303A1 (en) 1993-01-21
CA2073124A1 (en) 1993-01-04
NO934777L (no) 1994-02-11
KR100246681B1 (ko) 2000-04-01
US5552293A (en) 1996-09-03
EP0521842A3 (sv) 1994-01-26
HU9400011D0 (en) 1994-05-30
NO934777D0 (no) 1993-12-22
ATE171193T1 (de) 1998-10-15
CA2073124C (en) 2007-06-19
HU211512A9 (en) 1995-11-28
SE9102074D0 (sv) 1991-07-03
IE922188A1 (en) 1993-01-13
DK0521842T3 (da) 1999-06-14
EE03031B1 (et) 1997-08-15
JPH05276987A (ja) 1993-10-26
IL102390A (en) 1996-01-19
EP0521842B1 (en) 1998-09-16
AU658198B2 (en) 1995-04-06
JP3194020B2 (ja) 2001-07-30
DE69226990T2 (de) 1999-03-25
FI935970A (fi) 1993-12-31
HU218084B (hu) 2000-05-28
FI935970A0 (fi) 1993-12-31
DE69226990D1 (de) 1998-10-22
HUT71193A (en) 1995-11-28
NO315472B1 (no) 2003-09-08
WO1993001302A1 (en) 1993-01-21
NZ243435A (en) 1994-10-26
IE80841B1 (en) 1999-03-24
IL102390A0 (en) 1993-01-14
EP0521842A2 (en) 1993-01-07
AU1942592A (en) 1993-01-07
AU2292092A (en) 1993-02-11

Similar Documents

Publication Publication Date Title
FI109207B (sv) Tumör/kolhydratantigenspecifik monoklonal antikropp samt cellinje
JP3492373B2 (ja) モノクローナル抗体
JP4124486B2 (ja) ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用
CN111777681B (zh) 一种结合紧密连接蛋白-18.2的抗体及其用途
CN114514246A (zh) 对nectin-4具有特异性的抗体及其用途
JP2000511421A5 (sv)
JP2001501801A (ja) モノクローナル抗体ｂｒ１１０およびその使用
JP7063623B2 (ja) 治療用抗体およびその使用
PT94565B (pt) Novos anticorpos reactivos com carcinomas humanos
JP2935520B2 (ja) ガン治療に用いられる新規高親和性改変抗体系統群
IE60286B1 (en) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas
JP3631750B2 (ja) ヒトｍｄｒ１マルチドラッグ耐性遺伝子産物に対するモノクローナル抗体およびその使用
JP2007535907A (ja) 抗ヒドロキシラーゼ抗体およびその使用
US6787638B1 (en) Tumor specific human monoclonal antibodies and methods of use
EP4257612A1 (en) Development of new tumor engager therapeutic drug and use thereof
RU2268068C2 (ru) Новое антитело со специфичностью к злокачественной опухоли толстой кишки
EP4149543A1 (en) Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2021229104A1 (en) Anti-cd38 single-domain antibodies in disease monitoring and treatment

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: PHARMACIA AB

MA Patent expired